The rare kidney disorders market is projected to grow at a CAGR of 17%



Considering the rising unmet need associated with rare kidney disorders and the growing adoption of available treatment options, industry stakeholders have made significant investments to enable the development of novel drug candidates targeting this set of rare diseases

Press Release

Amazon Music Disney Promo


Roots Analysis has announced the addition of the Rare Kidney Disorders Market, 2022–2035” report to its list of offerings.


More than 90 candidates targeting rare kidney disorders are currently under clinical investigation, while several novel leads are being evaluated in the early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards the advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.



Key Market Insights


More than 125 drug candidates targeting rare kidney disorders are currently under development

Over 25 total pipeline candidates are available in the market across various geographical regions. Of these, 43% have been approved for the treatment of cystinosis, Fabry disease and lupus nephritis. Further, majority of the approved / under development drugs (47%) are designed for delivery via oral route.


Over 60 companies are engaged in the development of drugs targeting rare kidney disorders

Since 2006, 27 companies have been established in this domain. Further, around 60% of the developers are large and very large firms. In addition, majority (68%) of the players engaged in the development of drugs against rare kidney disorder are based in North America, primarily in the US.


Partnership activity in domain has increased at an annualized rate of >92%, during 2017-2021

It is worth mentioning that the maximum number of partnerships were inked in 2018 and 2019. Further, product development and commercialization agreements emerged as the most popular type of partnership model adopted by rare kidney disorder targeting drug developers, representing over 25% of the total instances.



To request a sample copy / brochure of this report, please visit this


For additional details, please visit or email [email protected]


You may also be interested in the following titles:

  1. Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035
  2. CAR-T Cell Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]